Double attack on Alzheimer's: new drug combo targets tau and amyloid

NCT ID NCT06602258

Ongoing Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding a new drug called E2814 to the existing Alzheimer's drug lecanemab can better slow the disease in people with early Alzheimer's. The study involves 105 participants and will measure changes in tau protein levels in spinal fluid and brain scans over up to 24 months. The goal is to see if hitting both tau and amyloid proteins is safe and more effective than lecanemab alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

E2814 (a drug targeting tau protein) and lecanemab (a drug targeting amyloid plaques)

What this could lead to

If successful, this combination therapy could slow or halt the progression of early Alzheimer's disease by attacking two key brain proteins at once.

What could go wrong

This is a small, early-phase trial focused on safety and biomarker changes, not yet on clear clinical benefit. The treatment may not slow memory loss or could cause side effects like brain swelling.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER S DISEASE

Contacts and locations

Show contact details

Locations

Abington Neurological Associates LTD

Abington, Pennsylvania, 19001, United States
Advanced Clinical Research Network

Miami, Florida, 33165, United States
Alzheimer's Research and Treatment Center

Wellington, Florida, 33467, United States
Alzheimer's Research and Treatment Center-Stuart

Stuart, Florida, 34997, United States
Axiom Brain Health

Tampa, Florida, 33609, United States
Banner Sun Health Research

Phoenix, Arizona, 85006, United States
Bradenton Research Center

Bradenton, Florida, 34205, United States
Charter Research

The Villages, Florida, 32162, United States
Columbus Memory Center, PC

Columbus, Georgia, 31909, United States
Hattiesburg Clinic

Hattiesburg, Mississippi, 39401, United States
K2 Medical Research

Clermont, Florida, 34711, United States
Keimei Memorial Hospital

Honjō, Miyazaki, 880-1111, Japan
Keio University Hospital

Shinjuku, Tokyo, 160-8582, Japan
Kerwin Memory Center

Dallas, Texas, 75231, United States
National Center for Geriatrics and Gerontology

Ōbu, Aichi-ken, 474-8511, Japan
National Clinical Research-Richmond, Inc

Richmond, Virginia, 23294, United States
National Hospital Organization Hiroshima-Nishi Medical Center

Ōtake, Hiroshima, 739-0696, Japan
Neurology Clinic, P.C.

Cordova, Tennessee, 38018, United States
Osaka Metropolitan University Hospital

Osaka, 545-8586, Japan
Progressive Medical Research

Port Orange, Florida, 32124, United States
Renstar Medical Research

Ocala, Florida, 34470, United States
Rijikai Medical Corporation Katayama Medical Clinic

Kurashiki, Okayama-ken, 710-0813, Japan
Tokyo Medical University Hospital

Shinjuku, Tokyo, 160-0023, Japan
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Yale University School of Medicine

New Haven, Connecticut, 06510, United States
Yamagata Tokushukai Hospital

Yamagata, 990-0834, Japan